在中国和远东，超过80%的肝细胞癌患者有慢性乙肝病毒的感染。
In parts of China and the Far East, over 80% of HCC patients have chronic HBV infection.
1998年首个核苷类似物药物拉米夫定推出之前，慢性乙肝病毒感染者可选的有效治疗途径一直都非常有限。
Effective treatment options for individuals with chronic hepatitis B infection were limited until 1998 when lamivudine, the first nucleoside analogue drug, was introduced.
全世界每三人中就有将近一人感染乙肝病毒(约20亿人)，而每十二人中就有一人(5.2亿多人)的生活与慢性乙型肝炎或慢性乙肝病毒感染相伴。
Nearly one out of every three people in the world (approximately 2 billion people) has been infected by HBV, and one in twelve (more than 520 million people) live with chronic HBV or HCV infection.
应用新型基因芯片研究乙肝病毒多点基因变异在慢性乙肝患者中的意义，为临床诊断和治疗提供依据。
ObjectiveTo study clinical meaning of new DNA chip technique in detecting the mutation of HBV-DNA , and to offer testimony for clinical diagnosis and treatment.
目的观察拉米夫定治疗儿童慢性乙型肝炎的临床疗效及对乙肝病毒标志物的影响。
Objective To observe the clinic effect of lamivudine in children with chronic hepatitis B and its influence of HBV markers.
方法随机筛选无乙肝病毒感染的慢性血吸虫病患者(实验组)24例，健康志愿者(对照组)26例。
Methods 24 patients with chronic or advanced schistosomiasis (experimental group) and 26 healthy volunteers (control group) all without hepatitis B virus infection were selected for the study.
结论苦参素与黄芪注射液具有良好的保肝、抗乙肝病毒、抗肝纤维化作用，治疗慢性乙型肝炎疗效确切。
Conclusion the combination of matrine and astragalus injection has satisfactory actions of protecting liver, anti-HBV and anti-fibrosis in the treatment of chronic hepatitis b.
目的应用新型基因芯片研究乙肝病毒多点基因变异在慢性乙肝患者中的意义，为临床诊断和治疗提供依据。
Objective To study clinical significance of DNA chip technique in detecting the mutation of HBV-DNA ORF, and to offer testimony for clinical diagnosis and treatment.
结论：拉米夫定治疗慢性乙肝及乙肝病毒携带者安全有效。
Conclusion: Lamivudin is efficient and safe medicine in the treatment of CHB and HBV carrier.
结论：拉米夫定治疗慢性乙肝及乙肝病毒携带者安全有效。
Conclusion: Lamivudin is efficient and safe medicine in the treatment of CHB and HBV carrier.
应用推荐